Rankings
▼
Calendar
MYGN Q4 2025 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena
MYGN
Myriad Genetics, Inc.
$487M
Q4 2025 Earnings
Healthcare
Medical - Diagnostics & Research
Income Statement
Revenue
$210M
-0.4% YoY
Gross Profit
$147M
70.0% margin
Operating Income
$120M
57.2% margin
Net Income
-$8M
-3.8% margin
EPS (Diluted)
$-0.08
QoQ Revenue Growth
+2.0%
Cash Flow
Operating Cash Flow
$11M
Free Cash Flow
$11M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$707M
Total Liabilities
$339M
Stockholders' Equity
$368M
Cash & Equivalents
$150M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$210M
$211M
-0.4%
Gross Profit
$147M
$151M
-2.7%
Operating Income
$120M
-$39M
+407.7%
Net Income
-$8M
-$43M
+81.4%
Geographic Segments
UNITED STATES
$197M
94%
Non-US
$13M
6%
← FY 2025
All Quarters